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Abstract 
Monocytes are an important immune cell type in chronic inflammatory conditions like 
atherosclerosis and heart failure. The increase in number of monocytes released to the 
peripheral blood circulation, the differentiation of monocytes to macrophages, and the 
presence of different macrophage subpopulations during pro- and anti-inflammatory 
stages of tissue injury may provide markers for monitoring inflammation. In particular, 
changes in monocyte iron metabolism during an inflammatory response may increase the 
possibility of tracking these immune cells non-invasively using magnetic resonance 
imaging (MRI). When secretion of the polypeptide hormone hepcidin is stimulated 
during inflammation, it binds the iron export protein ferroportin (FPN) on a limited 
number of cell types, including monocytes and macrophages. This ligand-receptor 
interaction leads to FPN internalization and downregulation through ubiquitin-mediated 
degradation. We hypothesized that hepcidin-mediated changes in monocyte iron 
regulation influence both cellular iron content and magnetic resonance (MR) relaxation 
rates. In response to varying conditions of extracellular iron supplementation, we 
observed THP-1 expression of FPN protein and its downregulation following hepcidin 
treatment. Also, in the presence hepcidin and iron supplementation, we detected a 
significant increase in the total transverse relaxation rate, R2*, compared to non-
supplemented cells. The positive correlation between total cellular iron content and R2* 
improved from moderate to strong in the presence of hepcidin. These in vitro findings 
suggest that hepcidin-mediated changes detected in monocytes using MRI could be 
valuable for cell tracking in vivo during an inflammatory response. 
Keywords  
Magnetic resonance imaging, Monocytes, Iron export, Ferroportin, Hepcidin, 
Inflammation. 
 
 
 
iii 
 
Summary (Lay abstract) 
Background: Inflammation is important in many diseases like cancer, heart failure and 
atherosclerosis. Inflammatory responses have many roles, including tissue repair and the 
elimination of harmful pathogens. This is partly accomplished by limiting the amount of 
iron required for bacterial growth. Although inflammation is part of wound healing even 
in conditions like heart disease, excess inflammation can lead to changes in the size, 
shape and function of the heart and eventually to heart failure. Therefore, clinical 
management of inflammation by distinguishing between pro- and anti-inflammatory 
responses is important but remains challenging for many reasons. To understand when 
interventions should be introduced to prevent excess inflammation, we propose the use of 
Magnetic Resonance Imaging (MRI) to noninvasively detect the activity of immune cells 
(like monocytes, a type of white blood cell) that play a major role in inflammation. In our 
molecular imaging approach, we track changes in cellular iron metabolism using MRI 
since changes in iron are regulated by the hormone, hepcidin and reflect stage of 
inflammation.   
Hypothesis: Hepcidin increases cellular iron content and MRI contrast in a laboratory 
model of human monocytes.  
Methods: Monocytes are cultured for one week in the absence and presence of iron 
supplement and hepcidin, to mimic the cellular environment after a heart attack. Small 
volumes of these cultured cells are then placed in a clinical MRI scanner and imaged.   
 Results and Significance: When monocytes were exposed to hepcidin, we observed an 
increase in both cellular iron and MRI contrast. This research may improve how we 
monitor cells responding to inflammation signals like hepcidin, in patients with 
conditions like cancer, heart failure and atherosclerosis. 
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Chapter 1: Introduction 
1.1 Systemic inflammatory response 
Inflammation is induced in response to host cell defense mechanisms against pathogens 
or endogenous stress signals. Inflammation is also a driving factor in many diseases like 
atherosclerosis, cancer and heart failure. In these diseases, an inflammatory response 
facilitates the elimination of invading pathogens, clearance of necrotic cells and repair of 
damaged tissues. This entails recruitment of inflammatory cells like lymphocytes, 
monocytes and neutrophils to the inflamed site [1]. Among these cell types, monocytes 
are the most abundant immune cell and play a major role in chronic inflammatory 
conditions like atherosclerosis and heart failure [2]. There are three distinct monocyte 
subsets reported in the literature, which express select proteins to varying degrees as 
denoted by +/- nomenclature. These are a) classical, classification determinant 
(CD)14++CD16- monocytes, b) intermediate CD14++CD16+ monocytes, and c) non-
classical CD14+CD16++ monocytes. In conditions like acute myocardial infarction (AMI) 
— where blockage of the coronary artery by atherosclerotic plaque causes tissue hypoxia, 
destabilizing the cell membrane of cardiomyocytes and leading to cell death [3] — there 
is an increase in intermediate CD14++CD16+ monocytes [4, 5]. These intermediate 
monocytes, therefore, may become a potential target population for therapeutic 
applications related to tracking the inflammatory response in disease.  
In response to growth factors and cytokines that are secreted during inflammation, 
infiltrating monocytes differentiate into macrophages [6]. Monocytes and macrophages 
produce a variety of cytokines, chemokines, growth factors and proteases to assist during 
both pro- and anti-inflammatory stages  [7]. Pro-inflammatory cytokines and chemokines 
promote immune cell infiltration and host cell secretion of antimicrobial molecules to 
eliminate microorganisms and reduce the chance of infection [8]; whereas, anti-
inflammatory cytokines and chemokines contribute to tissue repair and remodeling 
through phagocytosis of cell debris and inflammation resolution [9]. However, 
inflammation is not always successfully resolved, leading to inflammation associated 
disorders. For instance, chronic pro-inflammatory signaling may lead to hypoferremia 
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and tissue damage [10]. In conditions like AMI, a prolonged anti-inflammatory response 
can lead to left ventricular remodeling and heart failure [9].  
Methods that differentiate between pro- and anti-inflammatory responses are needed to 
improve therapeutic interventions. For example, if anti-inflammatory therapy is 
administered too early, this may increase the risk of infection [1, 9]. Since monocytes are 
the most abundant immune cell type present in chronic inflammatory conditions, tracking 
these cells with magnetic resonance imaging (MRI) may be useful for noninvasively 
monitoring systemic inflammatory responses and enhancing treatment options. 
1.2 Advancements in molecular imaging of inflammation 
Imaging modalities, including magnetic resonance imaging (MRI), hyperpolarized MRI, 
positron emission tomography (PET) and single photon emission computed tomography 
(SPECT), can be used to monitor inflammation [11, 12]. These modalities are currently 
used to monitor severe myocardial fibrosis or scar tissue formation, which changes the 
shape and function of the left ventricle and contributes to heart failure [11, 13]. 
Ultrasound and X-ray computed tomography (CT) have also proven useful in imaging 
inflammation in conditions like heart failure [14]. Nuclear medicine imaging using PET 
and SPECT have been applied to detect changes in molecular signaling pathways during 
inflammation [11]. Radioactive tracers used in PET and SPECT can be developed that 
bind to specific receptors on inflammatory cells, enabling cell tracking during an 
inflammatory response [15]. PET and SPECT scanners are commonly integrated with CT 
or MRI. Hybrid PET-CT and PET-MRI scanners allow for localization of molecular 
signaling during inflammation with high-resolution anatomical images [11, 16].   
Several clinically relevant PET tracers can be used to monitor inflammation. 18F-
fluorodeoxyglucose (FDG) PET can be used to assess myocardial viability post-AMI 
through differences in glucose utilization by cardiac tissue. This can be used to monitor 
recovery of the damaged myocardium as tracer uptake improves with revascularization, 
tissue healing and regeneration. FDG has also been used to monitor arterial inflammation 
in atherosclerosis, implicating macrophages in atherosclerotic plaques [17, 18]. 
Pentixafor, a 68Ga labelled PET tracer for monitoring inflammation, binds the C-X-C 
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chemokine receptor type 4 (CXCR4) that promotes leukocyte extravasation during 
inflammation [19]. Studies have shown increased uptake of Pentixafor in the initial stages 
of AMI [19, 20]. Isoquinoline carboxamide is a 11C labelled PET tracer used to monitor 
neuroinflammation in diseases like dementia [21]. This PET tracer acts as a ligand for 
translocator protein (TSPO) a transmembrane domain protein expressed in the outer 
mitochondrial membrane of microglia which is substantially upregulated in response to 
neuroinflammation [21].  Among the PET tracers above, 18F-FDG is most commonly 
used for imaging inflammation. However, 18F-FDG is taken up by monocytes, 
macrophages and other glucose metabolizing cells (muscle, brain, etc.) involved in pro- 
and anti-inflammatory responses at the site of inflammation, causing difficulties in 
differentiating between these two stages of the inflammatory response. PET also uses 
ionizing radiation which may limit its application in certain populations, including 
children and pregnant women. Although PET has superior sensitivity, its spatial 
resolution is inferior to other imaging modalities like MRI. 
MRI is a non-invasive imaging modality with high spatial resolution [22]. MRI can be 
used to study cardiac function, anatomy, inflammation post-AMI and myocardial 
stiffness. MRI is also used to monitor inflammation in conditions like breast cancer [22, 
23]. The use of contrast agents in MRI significantly improves the detection of inflamed 
tissue [24]. Gadolinium chelates are useful as exogenous contrast agents in monitoring 
inflammatory responses [25, 26]. Magnetic iron oxide nanoparticles (MNPs) are 
advantageous in monitoring scarce molecular targets related to inflammation, as these are 
small biologically inert molecules with high magnetic relaxation properties [26]. During 
an inflammatory response, MNPs are considered foreign bodies by innate immune cells 
and will be phagocytosed, enabling enhanced visualization of these inflammatory cells 
[26]. Perfluorocarbon nano-emulsions (19F) are also considered useful probes for imaging 
inflammation. Like MNPs, these 19F nano-emulsions are taken up by phagocytes during 
their migration to the site of inflammation, enabling detection of these cells in response to 
inflammation [24]. Overall, use of nonionizing radiation for repetitive imaging, high 
image resolution, multi-parametric imaging and hybrid imaging are the advantages of 
using MRI over other imaging modalities to monitor inflammation [27].   
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1.3 Systemic and cellular iron regulation 
1.3.1 Cellular iron regulation 
Iron is an important element for all living cells, required for DNA synthesis, respiration 
and oxygen transport [28]. However, excessive iron is cytotoxic and can cause diseases 
like cirrhosis and cardiomyopathy. Increased iron in regions of the brain has been linked 
to neurodegenerative diseases like Parkinson's and Alzheimer's [29]. On the other hand, 
iron deficiency can also be deleterious, causing cognitive defects in children as well as 
anemia in adults. Therefore, cellular iron content must be maintained within a narrow 
range through iron homeostasis to avoid adverse effects.  
Under normal conditions, 1–2 mg of dietary iron enters the serum daily via enterocytes of 
the small intestine [30]. Cellular iron regulation is mediated by several proteins which are 
regulated at transcriptional, post-transcriptional and post-translational levels. In 
mammals, serum iron is bound to a protein called transferrin (Tf, Figure 1). Each Tf 
molecule can bind two iron atoms in the ferric state (Fe+3). Tf-bound iron is internalized 
by cells through a receptor-mediated process involving transferrin receptor (TfRc) [30, 
31].  
Following cellular iron uptake, the reducing environment of the vesicle causes a 
transition from Fe+3 to the ferrous state (Fe+2). Fe+2 is then transported by a 
transmembrane protein found on the vesicle that was endocytosed, the divalent metal 
transporter (DMT 1), into the labile iron pool (LIP, Figure 1), a transitory redox active 
source of iron. Some of the iron in the LIP is then shuttled to ferritin protein complexes 
where it is oxidized and stored as Fe+3 [32]. There are two main ferritin subunits which 
are heavy (H) and light (L) ferritin. H-ferritin functions as a ferroxidase and facilitates 
oxidation of Fe+2. While some of the imported iron is used by intracellular processes, 
certain cells like monocytes and macrophages also export iron through ferroportin (FPN, 
Figure 1) [30, 33, 34].  
The iron response proteins (IRPs), IRP1 and IRP2, regulate iron uptake, storage, and 
export. When intracellular iron content is low, IRPs bind to iron response elements 
(IREs) on the 5ˈ end of the mRNA for ferritin and FPN to block translation and increase 
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cellular iron availability. In addition, under iron depleted conditions, IRPs bind to IREs 
on the 3ˈ end of TfRc mRNA to suppress its degradation, thereby increasing translation 
of TfRc [31, 35]. Conversely, in iron replete conditions, IRPs do not bind to IREs; 
causing more ferritin translation for extra iron storage, increasing translation of FPN for 
iron efflux and, lastly, downregulating TfRc mRNA to prevent more iron influx [30]. 
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Figure 1. Key features of mammalian iron regulation. Serum iron is mainly bound to 
transferrin (Tf) and imported into cells through receptor-mediated endocytosis by the 
transferrin receptor (TfRc). While a small amount of iron in the labile iron pool (LIP) is 
available for cellular activities, most intracellular iron is stored in ferritin. Only select 
cells, including monocytes and macrophages, export iron through ferroportin (FPN). The 
endocrine hormone, hepcidin, secreted from liver hepatocytes in response to 
inflammation and high serum iron, downregulates FPN.  
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1.3.2 Systemic iron homeostasis in humans 
Iron is essential to survival at the cellular level, but it plays an equally important role 
systemically. Dietary iron enters the circulation via enterocytes in the duodenum [36]. 
This is a crucial process, enabling hematopoiesis in the bone marrow (Figure 2). 
Although some iron is used for the generation of leukocytes and innate immune cells, 
most of the iron goes towards erythropoiesis. Approximately 22 mg of transferrin-bound 
iron per day is used to generate erythrocytes in the bone marrow and to produce 
hemoglobin. In fact, approximately 60-70% of the body’s iron resides in red blood cells 
[36]. 
Old and damaged red blood cells are recycled within the spleen and this essential process 
maintains the necessary iron levels, even when dietary iron uptake is limited. 
Macrophages and monocytes, the phagocytic cells in the reticuloendothelial system, 
recycle red blood cells to release iron trapped in hemoglobin. Recycled iron is then 
released into the circulation to be reused. Since erythropoiesis uses so many resources 
each day, the mechanisms responsible for recycling iron satisfy this daily requirement 
[36, 37].  
As at the cellular level, excess systemic iron can be dangerous; therefore, close to 20% of 
total iron is sequestered and stored within splenic macrophages and hepatocytes [36]. 
Systemic iron homeostasis is a tightly regulated process; for example, iron demand 
increases following blood loss, promoting the release of iron from macrophages, 
hepatocytes, and enterocytes. Once the demand for iron is alleviated, iron export from 
FPN-expressing cells decreases to maintain iron homeostasis [36, 38]. 
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Figure 2. Systemic iron regulation. Dietary iron is secreted into the circulation by 
enterocytes within the proximal small intestine. Circulating iron is then bound by proteins 
like transferrin. Transferrin-bound iron is transported through the circulation where it is 
used for hematopoiesis (mainly erythropoiesis) in the bone marrow. Damaged and old 
erythrocytes are removed from the bloodstream by macrophages in the 
reticuloendothelial (RE) system within the spleen and the iron is recycled back to the 
plasma. While all cells maintain stores of iron, hepatocytes, monocytes and macrophages 
store sizable amounts of iron [36].  
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1.3.3 Controlled regulation of iron export protein (FPN) 
The iron export protein FPN plays a vital role in regulating both systemic and cellular 
iron homeostasis. Both processes are tightly controlled to ensure survival and prevent 
disease. This includes regulation of FPN at transcriptional, post-transcriptional and post-
translational levels [39] all of which permit fine-tuned control of iron homeostasis.  
Btb and Cnc homology 1 (Bach1), a basic leucine zipper transcriptional repressor, 
controls FPN expression at the transcriptional level. When the antioxidant response 
element (ARE) in the promoter of FPN is bound by Bach1, FPN transcription is 
repressed, limiting FPN mRNA production and overall FPN protein levels. Heme 
reverses this process by causing the degradation of Bach1 and promoting ARE binding to 
nuclear factor erythroid 2-like (NRF2) protein, leading to transcriptional activation of 
FPN [40]. 
Iron also affects FPN expression in monocytes and macrophages at the post-
transcriptional level. FPN mRNA has a 5´ IRE, which binds to IRPs under iron deficient 
conditions, repressing FPN expression [41].  
At the post-translational level, FPN is controlled hormonally. When the polypeptide 
hormone hepcidin binds to FPN, it causes FPN internalization and degradation [42]. 
Hepcidin is released by hepatocytes during iron overload to prevent iron export from 
cells and limit plasma iron levels. Together, these different forms of FPN regulation 
allow for effective and reliable control of systemic and cellular iron metabolism under 
various circumstances.  
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1.4 Effect of hepcidin on monocyte iron regulation  
 Healthy humans maintain a plasma iron concentration between 5–30 µM and store 
approximately 0.2–1.0 g of iron within the cellular compartment. To maintain these 
healthy levels, iron absorption is increased in iron deficiency and decreased in iron 
overload conditions. These observations led to the discovery of hormonal iron regulation 
in mammals. The 25 amino acid polypeptide hormone hepcidin, post-translationally 
regulates iron export. Hepcidin acts as a ligand for the cell surface, iron export protein 
FPN, causing its phosphorylation, internalization and degradation, as mentioned above 
[43]. Following hepcidin binding to FPN, it will be phosphorylated then ubiquitin ligases 
add ubiquitin tags onto FPN, promoting its endocytosis (Figure 3). The polyubiquitin tail 
signals FPN for degradation via the lysosome, a protein complex containing proteases 
[44, 45].  This process decreases iron export in FPN-expressing monocytes, 
macrophages, enterocytes and hepatocytes. Between 10–100 nM hepcidin is required for 
FPN downregulation [43]. Hepcidin expression is controlled by plasma iron levels, 
erythropoietic needs, as well as inflammation. In response to increased plasma iron, the 
bone morphogenetic protein (BMP) and mothers against decapentaplegic (SMAD) 
pathways upregulate hepcidin transcription in hepatocytes. When BMP6 binds to its 
receptor in the presence of the co-receptor hemojuvelin, the SMAD signaling cascade is 
activated. The end result of this signaling pathway is phosphorylated SMAD protein 
complexes, translocating to the nucleus, binding to the 5ˈuntranslated region of the 
hepcidin gene and enhancing its transcription, thereby increasing hepcidin levels [46, 47].  
Hepcidin expression is upregulated during infection, acting as an anti-microbial peptide 
by decreasing the availability of circulating iron — an important cofactor for many 
pathogens [48]. In hepcidin deficient conditions like hereditary hemochromatosis, 
patients are more susceptible to certain bacterial infections caused by pathogens like 
Listeria monocytogenes due to excess iron in the plasma promoting bacterial growth [49].  
 Previous studies have shown increased expression of hepcidin mRNA in freshly isolated 
monocytes as well as in the human monocytic cell line THP-1 in response to 
proinflammatory mediators like lipopolysaccharide or interleukin (IL)-6 [50, 51]. 
However, the level of hepcidin mRNA expression in THP-1 cells was significantly lower 
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than that of liver hepatocytes. Monocytes express hepcidin for autocrine or paracrine 
regulation of FPN; however, the endocrine expression of hepcidin by hepatocytes far 
exceeds that of monocytes [52]. Since monocytes phagocytose damaged red blood cells, 
iron storage may increase in these cells during a pro-inflammatory response as increased 
levels of hepcidin downregulate FPN and prevent iron export [52, 53]. However, during 
an anti-inflammatory response, low hepcidin levels promote iron efflux from monocytes 
(through FPN), allowing more iron in plasma [42].   
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Figure 3. Hepcidin-mediated FPN degradation. Certain cells including monocytes and 
macrophages export iron through the protein ferroportin (FPN). When the hormone 
hepcidin is expressed, it acts as a ligand and binds FPN resulting in FPN phosphorylation. 
This is followed by ubiquitination by ubiquitin ligases. FPN ubiquitination drives its 
endocytosis where FPN is further ubiquitinated and degraded by the lysosome, thereby 
reducing iron export. In iron deficient conditions, hepcidin levels are reduced to enable 
FPN to export iron.  
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1.5 Magnetic resonance imaging (MRI) 
To better understand how variations in cellular iron content affect the magnetic resonance 
(MR) relaxation rates, MR physics will be discussed below. 
MRI is a noninvasive imaging modality with high spatial resolution and is used for the 
detection, diagnosis and monitoring of various medical treatments. The technology is 
based on the excitation of hydrogen atoms (protons) largely found in water molecules 
within tissues. This MR signal is then converted to an image, giving anatomical 
information about the subject [54].  
Protons within the atomic nuclei of hydrogen atoms have magnetic properties represented 
as nuclear spins. Thus, protons behave as tiny magnets with a magnetic moment (µ) that 
precesses randomly. The vector sum of all these magnetic moments is called the net 
magnetization vector (M0). Normally, the vector of these spinning magnetic moments is 
randomly distributed, leading to no net magnetization (M0 = 0). In the presence of an 
external magnetic field (B0), slightly more protons will align with B0 (parallel) than 
against B0 (anti-parallel), which creates a net magnetization in the direction of the B0 field 
(z-direction) [53]. Nuclear spins precess about the axis of the applied external magnetic 
field (B0) at the Larmor frequency (ω0) in radians/second, which is proportional to B0 in 
Tesla (T) as shown below. Larmor frequency (ω0) increases linearly with B0, and is also 
dependent on the gyromagnetic ratio (γ), a physical constant specific to the nuclei being 
imaged (γ/2π = 42.58 MHz/T for hydrogen protons) [54].   
                                                           ω0 = γ B0                              (1) 
The magnetic vector representing precessing protons can be broken down into two 
components: the longitudinal component (Mz) aligned with the direction of B0 (z-
direction) and the transverse component (Mxy) within the XY plane. Precession leads to 
rotation of the transverse component about the longitudinal (Z) axis. When spinning 
protons are subjected to B0 there are more low energy state spins aligned parallel with B0. 
The spins aligned against B0 are considered to be in a high energy state. Since an excess 
of spins aligns with B0, net/macroscopic magnetization has a longitudinal component 
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along the z-axis (Mz). Though the spins are rotating, but not in phase with each other, 
there is a null transverse microscopic magnetization (Mxy = 0) [54].   
Exchanging energy between two systems at a specific frequency is known as resonance. 
In MR, energy is exchanged between nuclear spins and an applied radiofrequency (RF) 
field which is a small magnetic field represented by B1. Only the protons that precess at 
the same frequency as the RF pulse (B1) will exchange energy with that RF pulse. Once 
B1 is applied, absorption of electromagnetic energy by the hydrogen nuclei will modify 
the spin equilibrium of the hydrogen protons. This is called excitation [54]. When these 
excited protons return to spin equilibrium, there is an emission of electromagnetic energy. 
Excitation of these protons causes changes to their energy levels and spin phases. At the 
quantum level, excitation leads to protons shifting from low energy state (parallel) to a 
high energy state (anti-parallel). This shift leads the macroscopic net magnetization 
vector to move to the XY plane. When considering the rotating frame of reference 
(Figure 4), net magnetization tips down during excitation and the flip angle (α°) is a 
function of the strength and duration of the RF pulse [54].  
As described above, the net magnetization has two components, the longitudinal 
component (Mz) and transverse component (Mxy). During excitation, longitudinal 
magnetization (Mz) decreases and transverse magnetization (Mxy) appears except for a 
180˚ flip angle (α°). As mentioned above, longitudinal magnetization is due to a different 
number of spins in parallel and anti-parallel states, and transverse magnetization is due to 
several spins getting into phase coherence. For example, during an excitation using an RF 
pulse with 90˚ flip angle, there is a null longitudinal magnetization (Mz = 0) due to an 
equal number of parallel and anti-parallel spins, but transverse magnetization (Mxy) exists 
due to all spins being in phase [54]. 
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Figure 4. Rotating frame of reference. Longitudinal magnetization (Mz) in the presence 
of an RF field (B1) tips down to the transverse plane (XY). Flip angle (α°) is a function of 
the strength and duration of B1. 
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Return of the excited spins to the equilibrium value M0 is called relaxation. During 
relaxation, the energy absorbed from B1 is emitted as a nuclear magnetic resonance 
(NMR) pulse. Relaxation combines two different mechanisms; longitudinal relaxation 
refers to the recovery of longitudinal magnetization and transverse relaxation refers to the 
decay of transverse magnetization. During longitudinal relaxation, energy is exchanged 
between the spins and surrounding lattice (spin-lattice relaxation). As spins lose energy 
from the high energy state to a low energy state, absorbed RF energy is released to the 
surrounding lattice. An exponential curve can be fitted to the recovery of longitudinal 
magnetization. The time taken for longitudinal magnetization (Mz) to reach 63% of its 
original value is called the longitudinal relaxation time (T1) as shown below [54].  
                                                             Mz = M0 ( 1 – exp - ( t / T1 ) )      (2) 
Transverse relaxation occurs due to dephasing of spins. When spins start to move 
together due to spin-spin interactions, their magnetic fields start to interact with each 
other. These spin-spin interactions, therefore, cause a cumulative loss in phase resulting 
in transverse magnetization decay. The decay of transverse magnetization (Mxy) is 
proportional to the acquired MR signal from the RF elements. The decrease in the signal 
intensity over time due to transverse relaxation is called free induction decay (FID). The 
decay of transverse magnetization can also be described by an exponential curve, where 
the time taken for transverse magnetization to decay up to 63% from its original value is 
the transverse relaxation time (T2) as show below [54]. 
                                                              Mxy = M0 exp - ( t / T2 )            (3) 
 Local magnetic field inhomogeneities may increase the decay of transverse 
magnetization (Mxy), resulting in an even shorter relaxation time, denoted by T2*. 
Relaxation values are tissue specific and T2 values are always shorter than T1. The three 
relaxation time constants (T1, T2 and T2*) can be interpreted as relaxation rates as 
follows: R1 = 1/T1, R2 = 1/T2 and R2* = 1/T2*. In order to determine the rate of decay of 
transverse relaxation related to local magnetic field inhomogeneities, denoted by R2', the 
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difference between R2* (due to spin-spin interactions and local magnetic field 
inhomogeneities) and R2 (due to only spin-spin interactions) should be calculated [54].  
                                                            R2' = R2* - R2                              (4)  
MRI has been evolving for many years, leading to improvements in the quality and speed 
of the signal acquisition. Each MRI sequence combines RF pulses and gradient magnetic 
fields to acquire a signal. Various MRI sequences have been established and depending 
on the type of sequence selected, the end goal is to acquire signals faster while 
minimizing image artifacts and maximizing the signal to noise ratio (SNR) [54].  
There are three main components of a sequence: RF pulses which are essential for the 
excitation (and subsequent relaxation) of hydrogen protons; gradient pulses which are 
used for spatial encoding; and arrangement of the gradient pulse which is used to 
determine how the k space (defined as an array of numbers representing spatial 
frequencies in the MR image) is filled, using different echo types to read the signal (e.g. 
spin echo, gradient echo; described below) [54]. 
1.5.1 Spin echo sequence   
Initially in the spin echo (SE) sequence, a 90˚ pulse is applied to tip the net magnetization 
in the Z axis into the XY plane. After the 90˚ pulse, a 180˚ pulse is applied at half of the 
echo time (TE/2). The purpose of the 180˚ pulse is to compensate for dephasing of the 
spins aligned in different positions in the XY plane, due to magnetic field 
inhomogeneities. Therefore, the 180˚pulse is used to re-phase the spins to obtain an echo 
that is weighted by T2. In a SE sequence, echo time (TE) is defined as the time interval 
between the 90˚ pulse and the signal acquisition at echo. The repetition time (TR) is the 
time interval between two 90˚ RF pulses. At TR, the SE sequence will be repeated, with 
each repetition filling a line of k space [54].   
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1.5.2 Inversion recovery spin echo sequence 
The inversion recovery SE sequence is used to obtain T1 weighted images and it is similar 
to that of the spin echo sequence (section 1.5.1). However, a 180° RF pulse (inversion 
pulse) is applied prior to the 90° excitation pulse to invert the longitudinal magnetization 
Mz. The time between the inversion pulse and 90° excitation pulse is called the inversion 
time (TI) [54]. 
1.5.3 Gradient echo sequence 
The gradient echo (GE) sequence uses a single RF pulse. The flip angle of the RF pulse 
applied in the GE sequence, denoting amount of spins tipped into the transverse plane, is 
always lower than 90˚. The consequence of using a lower flip angle for excitation is a 
faster recovery of the longitudinal magnetization, resulting in a decreased scan time. With 
the absence of a 180˚ pulse to re-phase spins, the loss of signal (T2*) is proportional to 
spin-spin interactions (T2) and magnetic field inhomogeneities [54].    
1.5.4 Tissue contrast and effect of iron on magnetic resonance 
signal 
Depending on TR,TE, and pulse sequence, different signal intensities between two tissues 
can be explained by their proton density, T1 and T2. For example, by setting TR to shorter 
values, relative intensities of two tissues are distinguishable by their T1. This is called T1-
weighted imaging. However, by setting TR to longer values, the T1 effect will be reduced 
and, given longer TE, tissue signal intensities will be altered by T2. This is called T2-
weighted imaging. These changes in tissue contrast depending on TR and TE are further 
enhanced by the use of contrast agents. Contrast agents will shorten the T1 and T2 
relaxation times of hydrogen nuclei located in their vicinity. Shortening of T1 will 
brighten the MR images while shortening of T2 will reduce the signal intensity and 
consequently darken the MR image [55]. Iron is a paramagnetic material which (in 
sufficient concentration) concentrates main magnetic field lines, creating field 
inhomogeneities resulting in faster dephasing of excited hydrogen protons in cells, 
thereby shortening T2 [56, 57]. Depending on the iron handling ability of different cell 
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types, this effect may enhance future possibilities of tracking the cells based on 
fluctuations in the MR signal.  
 
1.6 Overview of the thesis 
Monocytes are the most abundant cell type responding to chronic inflammatory diseases 
like atherosclerosis [18]. Since the number of monocytes released to the peripheral 
circulation is increased during an inflammatory response [18, 58], tracking these 
monocytes could provide a diagnostic tool for monitoring chronic inflammatory 
conditions such as atherosclerosis and heart failure [18]. Moreover, different monocyte 
sub-populations reflect pro- and anti-inflammatory stages and may serve as markers of 
the inflammatory process in specific tissues, like the failing heart [5, 6].  
The connection between inflammation and iron metabolism is specific to only a few cell 
types, including monocytes and macrophages, and raises the interesting possibility of 
tracking inflammation non-invasively using MRI. The polypeptide hormone hepcidin is 
secreted by the liver in response to inflammation. As the ligand for FPN, the iron export 
protein, hepcidin causes its post-translational degradation [59, 60]. This change in iron 
metabolism may influence MRI relaxation rates as M1 macrophages with relatively low 
FPN expression generally display an iron storage phenotype while M2 macrophages with 
generally high FPN expression typically exhibit iron recycling activity. Since monocytes 
are the precursors of macrophages, we investigated hepcidin-mediated changes in iron 
regulation and how it affects MR relaxation rates using the human THP-1 monocytic cell 
line.   
1.7 Hypothesis 
Hepcidin-mediated changes in monocyte iron regulation influence both cellular iron 
content and MR relaxation rates. 
1.8 Objectives 
The first objective was to investigate the expression of FPN in THP-1 monocytes. 
Changes in FPN expression in response to changes in extracellular iron were assessed by 
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Western blotting. We expected that THP-1 monocytes would express iron export protein 
in the presence of an extracellular iron supplement. Once the pattern of FPN expression 
was established, we investigated the effect of hepcidin on FPN degradation. Based on the 
literature, we expected FPN expression would be downregulated in response to hepcidin 
[44, 52, 61].  
The second objective was to characterize MR relaxation rates in THP-1 monocytes in 
response to changes in extracellular iron supplementation. MRI experiments were 
conducted to obtain the baseline MR signal (-Fe), the iron-supplemented MR signal (+Fe) 
and the MR signal after iron supplement was withdrawn from culture for 1, 2, 4 and 24 
hours. Results were compared to cells cultured in the presence of hepcidin. In response to 
hepcidin downregulation of FPN, we expected to see an increase in the MRI signal as 
intracellular iron levels increased.  
The third objective was to determine the total cellular iron content of THP-1 monocytes 
and examine the correlation to MR relaxation rates, in the presence and absence of both 
iron supplement and hepcidin. Inductively-coupled plasma mass spectrometry (ICP-MS) 
was used to determine the total cellular iron content. We expected that elemental iron 
content would increase in the presence of hepcidin and iron supplementation.  
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Chapter 2 
2.1 Introduction 
During an inflammatory response, circulating peripheral blood monocytes are recruited to 
the inflammation site by receptor-mediated interactions with chemokines. This monocyte 
activation leads to interactions with cell adhesion molecules on the activated endothelium 
and extravasation into target tissue [1]. Moreover, an increase in monocyte-related 
chemokines during inflammation leads to monocyte proliferation, directly correlating to 
an increase in the total number of monocytes [1]. Due to these inflammation-related 
chemokines, monocytes are one of the major immune cell types involved in chronic 
inflammatory conditions like atherosclerosis and heart failure. Furthermore, an increase 
in different monocyte sub-populations during pro- and anti-inflammatory stages may 
serve as markers for monitoring chronic inflammatory conditions [2, 3].  
During an inflammatory response, monocytes play a vital role in host defense 
mechanisms against pathogens by limiting the availability of iron required for bacterial 
growth. This is facilitated by upregulation of the endocrine hormone hepcidin [4]. During 
inflammation, hepcidin binds to the iron export protein FPN and induces its 
internalization and degradation, thereby increasing iron retention in monocytes and 
macrophages [5]. Monocytes are the precursors of macrophages, which can be divided 
into at least two categories: M1 (pro-inflammatory) and M2 (anti-inflammatory) 
macrophages. While there is a spectrum of macrophage phenotypes, in general, M1 
displays an iron storage phenotype while M2 exhibits an iron recycling phenotype [6]. 
These features of iron metabolism may allow us to differentiate between pro- and anti-
inflammatory stages using MRI.  
MRI is a noninvasive imaging modality that has been used to track cellular activities 
during inflammation [7, 8]. Iron-based contrast agents like superparamagnetic iron oxide 
particles have been developed to enhance image contrast and improve the tracking of 
inflammatory cells [7]. Since monocytes and macrophages are phagocytes, they 
internalize these exogenous contrast-enhancing particles thereby promoting more 
efficient tracking of these cells using MRI [7]. However, apart from phagocytic activity, 
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the effect of inflammation-associated changes in iron metabolism on the cellular MR 
signal have not been reported. In our study, we used the human monocyte THP-1 cell line 
to examine the endogenous cellular MR signal, varying extracellular iron and hepcidin to 
mimic the response to tissue injury (hemorrhage) and pro-inflammatory signaling [9], 
respectively.  
2.2 Materials and Methods 
2.2.1 Reagents 
Unless otherwise indicated, the reagents were purchased from Thermo Fisher Scientific, 
Mississauga, Canada and from Sigma-Aldrich, Oakville, Canada. 
2.2.2 THP-1 monocyte model 
Human THP-1 monocytes, derived from the peripheral blood of a male acute monocytic 
leukemia patient (ATCC TIB-202), were cultured as a cell suspension in RPMI-1640 
medium /10% fetal bovine serum /4 U/ml penicillin/4 µg/ml streptomycin/50 µM 2-
mercaptoethanol. Cells were incubated at 37˚C in a 5% CO2/air mixture. Cultures were 
maintained between 2-8 × 105 cells/ml based on cell counts determined through 
hemocytometry. 
2.2.3 Iron supplementation   
THP-1 cells were resuspended at a concentration of 2–4x105 cells/ml and cultured in the 
absence (-Fe) or presence (+Fe) of iron-supplemented medium containing 25µM ferric 
nitrate for 7 days (Figure 5A). Iron-supplemented cells were then returned to non-
supplemented medium and cultured for an additional 1 (1h-Fe), 2 (2h-Fe), 4 (4h-Fe), and 
24 (24h-Fe) hours (Figure 5B). At each time point, cells were collected in 850 µl 
radioimmunoprecipitation assay buffer (RIPA; 10 mM Tris-HCl pH 7.5/140 mM 
NaCl/1% NP-40/1% sodium deoxycholate/0.1% sodium dodecyl sulfate [SDS]) 
containing 150 μl Complete Mini protease inhibitor cocktail (Roche Diagnostic Systems, 
Laval, Canada) for protein analysis. 
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2.2.4 Hepcidin treatment 
To examine the response of THP-1 monocytes to hepcidin, cells were cultured in the 
presence and absence of iron supplement, as described above, and in the presence of 200 
ng/ml hepcidin for up to 24 hours (Figures 5C and 5D). Following hepcidin treatment, 
cells were prepared for protein analysis, elemental iron analysis or MRI. 
For MRI experiments, THP-1 monocytes subjected to different iron treatment conditions 
in the presence and absence of hepcidin were collected intact by centrifugation at 300×g 
and 15˚C for 5 minutes. After centrifugation medium was removed  and cells were 
washed three times with phosphate buffered saline pH 7.4 (PBS), cells were then 
centrifuged at 300 × g at 15˚C for 5 minutes in custom made Ultem wells (inner diameter: 
4 mm; height: 10 mm, Lawson Imaging Prototype Lab). Once the cells were loaded into 
the Ultem wells, MRI relaxation rates were measured as described in section 2.2.8.  
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Figure 5. THP-1 cell treatments for Western blot and MRI. Cells were cultured in the 
absence (-Fe) or presence (+Fe) of iron supplementation (25 µM ferric nitrate/medium) 
for 7 days (A) and then harvested either immediately (-Fe and +Fe) or 1 (1h-Fe), 2 (2h-
Fe), 4 (4h-Fe) and 24 (24h-Fe) hours after removal of extracellular iron supplement (B). 
Similarly, cultured cells were treated with 200 ng/ml hepcidin for up to 24 hours of 
culture prior to harvest (C and D).  
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2.2.5 Protein preparation and bicinchoninic acid assay 
For Western blots and elemental iron analysis, cells cultured under different conditions 
(Figure 5) were centrifuged at 300 x g for 5 mins at 15°C. The supernatant was discarded, 
and the cell pellet was collected in 850 µL RIPA buffer with 150 μL Complete Mini 
protease inhibitor cocktail. Samples were placed on ice and complete cell lysis was 
achieved by sonicating three rounds, each for 12 seconds using the Sonic Dismembrator 
500 (Fischer Scientific, Pittsburg, USA). Protein concentrations were determined using 
the bicinchoninic acid assay (BCA) with bovine serum albumin (BSA) as the protein 
standard [10]. 
 
2.2.6 Western blot 
Samples containing total cellular protein, described in sections 2.2.3 and 2.2.4, were 
separated by SDS polyacrylamide gel electrophoresis (SDS-PAGE) according to 
published procedures [11]. Samples were assessed under reducing conditions using 1 mM 
dithiothreitol. Each sample contained 20 µg protein and was separated based on protein 
size using a 5% stacking gel and a 10% running gel. Molecular weight (M.W.) standards 
were run alongside protein samples for size comparison. 
Separated protein was transferred to a nitrocellulose blot (iBlot Gel Transfer Stacks) 
following the manufacturer’s protocol and published procedures [12]. To block 
nonspecific binding, the blot was incubated in 6% BSA/10 mM Tris HCl pH 7.4/0.9% 
NaCl buffered saline (Tris buffered saline, TBS)/0.02% sodium azide (TBSA) for a 
minimum of 2 hours at room temperature. To check for expression of FPN protein, the 
blot was incubated overnight at room temperature in 1:2000 rabbit anti-FPN 
/3%BSA/TBSA. After incubation with primary antibody, blots were washed for 30 
minutes with 4 changes of TBS/0.1% Tween 20 (TBST) and then incubated for 2 hours at 
room temperature in 1:10,000 horseradish peroxidase (HRP)-conjugated goat anti-rabbit 
immunoglobulin (Ig) /1% BSA/TBS. After incubation in secondary antibody, blots were 
washed with TBST for 30 minutes with two changes of buffer. Bands were developed 
using the SuperSignal West Pico Chemiluminescent Substrate, detecting signal with the 
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ChemiDoc® Imaging System (Syngene, Fredrick, USA). The M.W. of FPN is 
approximately 63 kDa [13].  
FPN expression was compared to the glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) control. Blots were stripped in solution containing 245 mM β-
mercaptoethanol/2% SDS/62.5 mM tris-hydrochloric acid (pH6.8) and reprobed as 
described above, using 1:2000 rabbit anti-GAPDH as the primary antibody. The M.W. of 
GAPDH is approximately 37 kDa.  
Expression of FPN was analyzed by densitometry using ImageJ software. The signal 
intensity of FPN was normalized to the signal intensity of GAPDH. 
 
2.2.7 Trace elemental iron analysis 
For elemental iron analysis, samples containing 2–4 mg/ml protein were prepared as 
indicated in section 2.2.5. The amount of iron in each sample was measured using 
inductively-coupled plasma mass spectrometry (ICP-MS, Biotron Analytical Services, 
Western University) and reported as total cellular iron content normalized to total amount 
of protein.  
 
2.2.8 MRI phantoms 
Each sample consisted of approximately 40–50 million cells placed in an Ultem well 
prior to mounting in a 9 cm, spherical 4% gelatin (porcine type A)/PBS phantom (Figure 
6A) [14]. Cell phantoms were scanned at 3T on a Biograph mMR (Siemens AG, 
Erlangen, Germany) using previously developed sequences to acquire relaxation rates 
[14]. Single echo spin echo and multi-echo gradient echo sequences were applied to 
obtain R2 and R2*, respectively. R2′ was calculated by subtraction (R2* ⁻ R2) [14]. The 
following imaging parameters were used for MR image acquisition. For R1, longitudinal 
relaxation rate, an inversion recovery spin echo sequence was used. The slice thickness 
was 3 mm (Figure 6B), the field of view was 120 × 120 mm, matrix size was 128 × 128 
mm, voxel size was: 3.0 × 0.9 × 0.9 mm3, repetition time (TR) was: 4000 ms, flip angle 
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was 90˚, inversion times were 22, 200, 500, 1000, 2000 and 3900 ms and echo time (TE) 
was 13 ms. For both single echo spin echo and multi-echo gradient echo sequences, slice 
thickness was 3 mm (Figure 6B), the field of view was 120 × 120 mm, matrix size was 
192 × 192 mm and voxel size was 3.0 × 0.6 × 0.6 mm
3. For the single echo spin echo 
sequence, TEs were 13, 20, 25, 30, 40, 60, 80, 100, 150, 200 ms; TR was 2010 ms; flip 
angle was 90˚; and scanning time was approximately 61 minutes. For multi-echo gradient 
echo, TEs were 6.12, 14.64, 23.16, 31.68, 40.2, 50, 60, 70, 79.9 ms; TR was 200 ms; flip 
angle was 60˚ and scanning time was approximately 25 minutes. 
Transverse relaxation rates (R2* and R2) were measured using software developed in 
Matlab 7.9.0 (R2010b). This software was used to determine the region of interest (ROI) 
when measuring R2* and R2 signals. The ROI included 21 voxels within the sample, 
avoiding the wall of the well. Relaxation rates were calculated using the average signal 
intensity and least-squares curve fitting. Relaxation rates were reported as the mean +/- 
standard error of the mean (SEM) using GraphPad Prism software, version 8.0.0.  
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Figure 6. MRI gelatin phantom and slice localization. A. Cells in Ultem wells were 
mounted in one hemisphere of a 9 cm spherical phantom and overlaid with 4% 
gelatin/PBS. In the final assembly, this hemisphere was secured to a gelatin-only 
hemisphere to give the overall 9 cm sphere. A plastic marker was used as an indicator of 
sample layout [14]. B. To acquire MR images, the cell phantom was placed in a knee 
coil. Yellow lines in the locator image indicate the 3 mm slice thickness through the 
samples.   
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2.2.9 Statistical analysis 
Statistical analyses were performed using SPSS, version 25. MR relaxation rates obtained 
for treatment time points, reflecting changes in extracellular iron supplementation or 
hepcidin treatment, were analyzed using one-way analysis of variance (ANOVA). 
Significant differences were defined by p < 0.05. To test the effect of the combination of 
hepcidin and iron supplementation on MR relaxation rates, two-way ANOVA was 
conducted to determine significant differences. Pearson’s correlations were assessed to 
determine the relationship between total cellular iron content and MR relaxation rate. A 
linear regression model was applied using cellular iron content as the independent 
variable and MR relaxation rate as the dependent variable to obtain the line of best fit. 
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2.3 Results 
2.3.1 Effect of iron and hepcidin on FPN expression 
To obtain evidence of iron export activity in THP-1 monocytes, cultured cells were 
incubated in the presence and absence of iron supplementation. Western blots revealed 
FPN expression in all samples (Figure 7A). Under standard culture conditions (-Fe), 
THP-1 cells express maximal levels of iron export protein, similar to the level of GAPDH 
expression (ratio ~1 in Figure 7C). Moreover, after 7 days of iron supplementation (+Fe), 
there is little or no change in the expression of FPN, as confirmed by densitometry 
(Figure 7C, blue bars). However, up to two hours after the withdrawal of iron 
supplement, FPN expression significantly declines (+Fe versus 1h-Fe, p < 0.01; +Fe 
versus 2h-Fe, p < 0.01), before significantly recovering at 4 hours after the withdrawal of 
extracellular iron (2h-Fe versus 4h-Fe, p < 0.05; Figures 7A and 7C, blue bars). After 24 
hours of iron supplement withdrawal (24h-Fe), FPN expression significantly decreases 
(+Fe versus 24h-Fe and 4h-Fe versus 24h-Fe, p < 0.001)  
To determine the effect of the polypeptide hormone hepcidin on FPN expression, cells 
were treated with exogenous hepcidin (Figure 7B). Potential changes in FPN expression 
in response to hepcidin were assessed using the Western blot to track protein degradation. 
One-way ANOVA suggests FPN expression significantly decreases (Figure 7C) at 4 and 
24 hours of iron supplement withdrawal in hepcidin-treated samples (+Fe orange versus 
4h-Fe orange, p < 0.01; +Fe orange verses 24h-Fe orange, p < 0.05). 
 Two-way ANOVA comparing hepcidin treated and untreated samples (red lines) 
indicates that at baseline (-Fe), FPN expression was significantly decreased in response to 
hepcidin (-Fe blue verses -Fe orange, p < 0.001), confirming a biologically meaningful 
interaction. Also, in the +Fe sample, FPN expression indicates a significant decrease (+Fe 
blue versus +Fe orange, p < 0.001). Interestingly, one hour after the removal of iron 
supplement and hepcidin treatment (1h-Fe), FPN is still expressed at a low level, 
suggesting little influence of exogenous hepcidin. This decreases even further after 4 
hours of iron supplement withdrawal (4h-Fe blue versus 4h-Fe orange, p < 0.001) 
suggesting that FPN expression is down-regulated in the presence of hepcidin at these 
timepoints.  
 
 
38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*** *** *** 
** ** * *** 
** * 
A
A 
B
B 
C
C 
 
 
39 
 
Figure 7. Regulation of ferroportin (FPN) expression in THP-1 monocytes by 
extracellular iron and hepcidin. THP-1 cells were cultured for 7 days in the absence (-
Fe) or presence (+Fe) of iron-supplemented medium containing 25 µM ferric nitrate. 
Cells were either harvested immediately or after the withdrawal of iron supplement and 
culture for an additional 1 (1h-Fe), 2 (2h-Fe), 4 (4h-Fe) and 24 (24h-Fe) hours. To 
examine FPN regulation, -Fe and +Fe samples were grown in the presence of 200 ng/ml 
hepcidin for the last 24 hours of culture while hepcidin was added to all other samples 
after the removal of iron supplement. Representative Western blots show the change in 
FPN expression in the absence (A) and presence (B) of hepcidin (refer to Appendix E for 
additional immunoblot results). Molecular weight standards are indicated on the left 
while GAPDH provided a loading control. Densitometry (C) indicates relative level of 
FPN expression normalized to GAPDH (n = 3 independent experiments, * p < 0.05, ** p 
< 0.01, *** p < 0.001).   
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2.3.2 Effect of hepcidin on cellular iron content 
 Despite changes in FPN expression, cellular iron content does not change significantly 
across all time points, regardless of changes in iron supplementation (Figure 8A). There 
was no correlation between the ratio of FPN/GAPDH and total cellular iron content. 
Elemental iron analysis using ICP-MS shows cellular iron content ranges between 0.175–
0.679 µg/mg protein, indicating a modest rise in iron content and return to the baseline.    
However, in the presence of iron supplementation and hepcidin (+Fe) there is a 
significant increase (p < 0.01) in total cellular iron content (Figure 8B) compared to the 
baseline control (-Fe versus +Fe, p < 0.01). Subsequently, one hour after the withdrawal 
of iron supplement (1h-Fe), hepcidin treatment results in a significant decrease in total 
cellular iron content (+Fe versus 1h-Fe, p < 0.05, Figure 8B). Interestingly, two hours 
after the removal of iron supplement (2h-Fe), hepcidin treatment results in a second 
increase in total cellular iron content (1h-Fe versus 2h-Fe, p < 0.001) which is sustained 
up to 4h-Fe and then followed by a significant decrease in cellular iron content (4h-Fe 
versus 24h-Fe, p < 0.01). These data reflect a biphasic response of THP-1 cells to 
hormonal treatment with hepcidin.  
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Figure 8. Influence of extracellular iron and hepcidin on intracellular iron content. 
To examine the effect of changes in extracellular iron (A), THP-1 cells were cultured for 
7 days in the absence (-Fe) or presence (+Fe) of iron-supplemented medium containing 
25 µM ferric nitrate. Cells were either harvested immediately (-Fe and +Fe) or after 
removal of iron supplement and culture for an additional 1 (1h-Fe), 2 (2h-Fe), 4 (4h-Fe) 
or 24 (24h-Fe) hours in non-supplemented medium. To examine the regulation of iron 
export (B), -Fe and +Fe samples were grown in the presence of 200 ng/ml hepcidin for 
the last 24 hours of culture while hepcidin was added to all other samples after the 
removal of iron supplement. Total cellular iron content was assessed by ICP-MS and was 
normalized to protein concentration. In response to changes in extracellular iron, the total 
intracellular iron content ranged between 0.175 and 0.679 µg/mg protein but was not 
significantly different between samples (n = 3-4). However, in the presence of hepcidin, 
iron-supplemented cells (+Fe) retained significantly more cellular iron than non-
supplemented cells (-Fe) but returned to baseline values within 1 hour after the 
withdrawal of iron supplement. A biphasic response to the addition of hepcidin was 
observed between 2 and 24 hours after the withdrawal of iron supplement (2h-Fe to 24h-
Fe; n = 3-4). * p < 0.05, ** p < 0.01, *** p < 0.001.  
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2.3.3 Effect of iron supplement on transverse relaxivities 
To examine the effect of changes in extracellular iron on transverse relaxivity, THP-1 
monocytes were mounted in an MR phantom and scanned at 3T. Mean transverse 
relaxation rate of these cells under different conditions of iron treatment indicates a 
relatively high signal (approximately > 10 Sec-1) for both the total transverse relaxation 
rate (R2*, Figure 9A) and its irreversible component (R2, Figure 9B). Neither R2* nor R2 
was influenced by continuous iron supplementation (+Fe) compared to the control culture 
(-Fe).  However, withdrawal of iron supplementation for 1 (1h-Fe) to 4 (4h-Fe) hours 
significantly increased the R2* signal (+Fe versus 1h-Fe, p < 0.01; +Fe versus 2h-Fe, p < 
0.001; +Fe versus 4h-Fe, p < 0.01). But, by 24 hours (24h-Fe), R2* returned to baseline 
values (4h-Fe versus 24h-Fe, p < 0.01; Figure 9A).  
The effect of iron supplement withdrawal on R2 was not apparent for 4 hours (4h-Fe) at 
which point R2 significantly increased over baseline values (-Fe versus 4h-Fe, p < 0.05) 
before returning to control levels (4h-Fe versus 24h-Fe, p < 0.01). 
The R2* signal is made up of two components: reversible R2′ and irreversible R2. 
Consistent with R2* and R2, the R2′ signal (Figure 9C) showed no significant change in 
the presence of iron supplementation (+Fe) compared to the control culture (-Fe). 
However, R2′ significantly increased 1 (1h-Fe) to 4 (4h-Fe) hours after iron supplement 
was withdrawn (+Fe versus 1h-Fe, p < 0.01; +Fe versus 2h-Fe, p < 0.001; +Fe versus 4h-
Fe, p < 0.05). By 24 hours after the removal of iron supplement (24h-Fe), R2′ returned to 
baseline values (4h-Fe versus 24h-Fe, p < 0.001).  
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Figure 9. Influence of extracellular iron on transverse relaxation rates in human 
monocytes. To examine the influence of extracellular iron, THP-1 cells were cultured in 
the absence (-Fe) or in the presence (+Fe) of iron-supplemented medium containing 25 
µM ferric nitrate for 7 days. Cells were then harvested and scanned either immediately (-
Fe and +Fe) or cultured for an additional 1 (1h-Fe), 2 (2h-Fe), 4 (4h-Fe) and 24 (24h-Fe) 
hours after removal of extracellular iron supplement. One-way ANOVA indicates 
significant changes between samples subjected to iron treatments. A. Regardless of iron 
supplementation (+/- Fe), human THP-1 cells displayed relatively high transverse 
relaxation rates (R2*). However, within an hour of iron supplement withdrawal, R2* 
significantly increased and remained elevated up to 4 hours before returning to baseline. 
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B. The irreversible component of transverse relaxivity (R2) is increased modestly at 4h-
Fe before returning to baseline. C. Like R2*, the reversible component (R2′ = R2* ‒ R2) 
increased significantly upon withdrawal of iron supplementation and also remained 
elevated up to 4 hours before returning to baseline (n = 3-4, * p < 0.05, ** p < 0.01, *** p 
< 0.001). 
2.3.4 Effect of hepcidin on transverse relaxivities 
THP-1 cells were incubated with various amounts of iron supplement and hepcidin before 
scanning at 3T to measure relaxation rates. The mean values of R2*, R2 and R2' are shown 
in Figure 10. By adding hepcidin, we aimed to interrupt the iron export activity of 
monocytes. Total transverse relaxation rate (R2*) significantly increased (p < 0.05) in the 
presence of iron supplementation and hepcidin (-Fe versus +Fe, Figure 10A) and 
remained high for 1 hour after withdrawing iron supplementation (+Fe versus 1h-Fe). 
However, 2 hours after iron supplementation withdrawal (2h-Fe) R2* significantly 
increased again (1h-Fe versus 2h-Fe, p < 0.001) and remained high until 4 hours after 
iron supplement withdrawal when the signal returned to baseline (4h-Fe versus 24h-Fe, p 
< 0.001).  
Under the same conditions, the irreversible component (R2, Figure 10B) showed 
significant changes similar to R2*. 
The reversible component (R2', Figure 10C) remained unchanged in the presence of iron 
supplement (+Fe) compared to the baseline (-Fe). However, R2′ significantly increased (p 
< 0.01) after 2 hours of iron withdrawal (-Fe versus 2h-Fe, p < 0.01; 1h-Fe versus 2h-Fe, 
p < 0.01) before returning to baseline (2h-Fe versus 24h-Fe, p < 0.01).  
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Figure 10. Influence of extracellular iron and hepcidin on transverse relaxation 
rates in human monocytes. To examine the influence of extracellular iron and hepcidin, 
THP-1 cells were cultured in the absence (-Fe) or in the presence of (+Fe) iron-
supplemented medium containing 25 µM ferric nitrate for 7 days. Cells were harvested 
either immediately or 1 (1h-Fe), 2 (2h-Fe), 4 (4h-Fe) and 24 (24h-Fe) hours after removal 
of extracellular iron supplement. Also, -Fe and +Fe samples were grown in the presence 
of 200 ng/ml hepcidin for the last 24 hours of culture while hepcidin was added to all 
other samples after the removal of iron supplement. One-way ANOVA indicates 
significant changes between samples subjected to iron and hepcidin treatments. A. In the 
presence of iron supplementation (+Fe), human THP-1 cells display a significant increase 
in the total transverse relaxation rate (R2*). For the first hour after iron supplement 
withdrawal, R2* remains relatively constant. B. The irreversible component (R2) also 
increased significantly in the presence of iron. C. The reversible component (R2′) was 
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only significantly increased two hours after iron supplement withdrawal. n = 3-4, * p < 
0.05, ** p < 0.01, *** p < 0.001 
2.3.5 Comparison of transverse relaxivities between hepcidin 
treated and untreated THP-1 cells. 
The influence of hepcidin on THP-1 samples was evaluated using two-way ANOVA. 
Figure 11 indicates that in the presence of both hepcidin and various levels of 
extracellular iron, there are significant changes in relaxation rates. R2* (Figure 11A) 
significantly increases (p < 0.05) in the presence of both extracellular iron and hepcidin 
(+Fe, orange bar) compared to monocytes treated with iron alone (+Fe, blue bar). R2* 
also significantly decreases within 1 hour of iron supplement withdrawal (1h-Fe) in the 
presence of hepcidin (orange bar versus blue bar). There was no influence of exogenous 
hepcidin on R2* at any other time point. Likewise, R2 was not influenced by hepcidin 
(Figure 11B) under any of the conditions examined. A comparison between R2′ (Figure 
11C) signals indicates that hepcidin predominantly influences the reversible component 
of transverse relaxation rate.   
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Figure 11. Influence of extracellular iron and hepcidin on transverse relaxation 
rates in human monocytes. To examine the influence of extracellular iron and hepcidin, 
THP-1 cells were cultured in the absence (-Fe) or in the presence of (+Fe) iron-
supplemented medium containing 25 µM ferric nitrate for 7 days. These samples were 
treated with 200 ng/ml hepcidin for the last 24 hours of culture. Cells were harvested 
either immediately or 1 (1h-Fe), 2 (2h-Fe), 4 (4h-Fe) and 24 (24h-Fe) hours after removal 
of extracellular iron supplement. Also, these samples were treated with 200 ng/ml of 
hepcidin for up to 24 hours before the harvest. Two-way ANOVA indicates significant 
changes between samples treated in the presence and absence of hepcidin. Both R2* (A) 
and R2′ (C) relaxation rates increase significantly in the presence of iron supplement and 
hepcidin, with a significant decrease within an hour of iron supplement withdrawal. The 
irreversible component R2 (B) is not significantly influenced by hepcidin. n = 3-4, * p < 
0.05, ** p < 0.01 
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2.3.6 Influence of iron supplement and hepcidin on 
longitudinal relaxivity 
 The R1 signal remained constant across all treatment conditions and time points in 
samples without hepcidin (Figure 12A). However, in the presence of hepcidin (Figure 
12B), longitudinal relaxation rate significantly increased upon iron supplementation (-Fe 
versus +Fe, p < 0.01) and remained elevated up to four hours after the removal of iron 
supplement. Comparison of hepcidin treatment using two-way ANOVA (Figure 12C) 
showed a significant decrease in R1 (p < 0.05) at 1h-Fe in the presence of hepcidin. 
Regardless, there was no significant change in cellular iron content with and without 
hepcidin at 1h-Fe.   
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Figure 12. Influence of extracellular iron and hepcidin on longitudinal relaxation 
rates. To examine the influence of extracellular iron and hepcidin, THP-1 cells were 
cultured in the absence (-Fe) or presence (+Fe) of iron-supplemented medium containing 
25 µM ferric nitrate for 7 days. These samples were treated with 200 ng/ml hepcidin for 
the last 24 hours of culture. Cells were harvested either immediately or 1 (1h-Fe), 2 (2h-
Fe), 4 (4h-Fe) and 24 (24h-Fe) hours after removal of extracellular iron supplement. 
Also, these samples were treated with 200 ng/ml of hepcidin for up to 24 hours before the 
harvest. One-way ANOVA indicates, A. In the absence of hepcidin, R1 remains relatively 
constant across all samples. B. In the presence of hepcidin, R1 significantly increased 
following iron supplementation (+Fe) and remained elevated up to 4 hours after the 
withdrawal of iron supplement. Two-way ANOVA indicates, C. In the presence of 
hepcidin, there was a significant decrease in R1 at 1h-Fe. n = 3, * p < 0.05, ** p < 0.01 
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2.3.7 Correlation between cellular iron content and transverse 
relaxivities 
To understand the correlation between cellular iron content (the independent variable) 
and transverse relaxation rate (the dependent variable), Pearson’s correlation test was 
performed. There was a moderate positive correlation (Figure 13A, r = 0.62, p < 0.01) 
between cellular iron content and the total transverse relaxation rate, R2*; however, no 
correlation was obtained between cellular iron content and the irreversible R2 component 
of transverse relaxation rate. In THP-1 monocytes, the moderate positive correlation 
(Figure 13B, r = 0.61, p < 0.01) between cellular iron content and transverse relaxivity 
rests with the reversible R2′ component. The lines of best fit were determined using a 
linear regression model and an independent samples t-test indicates these relationships 
have similar slopes, between 5.8 and 8.8. 
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Figure 13. Influence of changes in extracellular iron on the correlation between 
cellular iron content and MR transverse relaxation rates. To examine the influence of 
extracellular iron, THP-1 cells were cultured in the absence (-Fe) or in the presence (+Fe) 
of iron-supplemented medium containing 25 µM ferric nitrate for 7 days. Cells were then 
harvested and scanned either immediately (-Fe and +Fe) or cultured an additional 1 (1h-
Fe), 2 (2h-Fe), 4 (4h-Fe) and 24 (24h-Fe) hours after removal of extracellular iron 
supplement. Total cellular iron content was assessed by ICP-MS and was normalized to 
protein concentration. There is a moderate positive correlation between cellular iron 
content and both R2* (A) and R2' (B). For both graphs, n = 19 and p < 0.01. 
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For the samples treated with hepcidin, Pearson’s correlation analysis shows a strong 
positive correlation between cellular iron content and R2* (Figure 14A, r = 0.80, p < 
0.001). Surprisingly, after THP-1 monocytes are treated with hepcidin, there is a 
moderate positive correlation between cellular iron content and both R2 (Figure 14B, r = 
0.71, p < 0.01) and R2′ (Figure 14C, r = 0.75, p < 0.001). Using a linear regression model, 
the lines of best fit were determined. An independent samples t-test indicates that the 
slopes of these lines are similar for all transverse relaxation rates. Moreover, comparison 
of the slopes between hepcidin treated and untreated samples revealed there were no 
significant changes in the slope when samples were exposed to hepcidin.   
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Figure 14. Influence of hepcidin on the correlation between cellular iron content and 
transverse relaxation rates. To examine the influence of extracellular iron and hepcidin, 
THP-1 cells were cultured in the absence (-Fe) or in the presence of (+Fe) iron-
supplemented medium containing 25 µM ferric nitrate for 7 days. These samples were 
treated with 200 ng/ml hepcidin for the last 24 hours of culture. Cells were harvested 
either immediately or 1 (1h-Fe), 2 (2h-Fe), 4 (4h-Fe) and 24 (24h-Fe) hours after removal 
of extracellular iron supplement. Also, these samples were treated with 200 ng/ml of 
hepcidin for up to 24 hours before the harvest. The total cellular iron content was 
assessed by ICP-MS and normalized to protein concentration. A.  There is a strong 
correlation between cellular iron content and R2* (p < 0.001). B. There is a moderate 
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correlation between cellular iron content and R2 (p < 0.01) C. There is also a moderate 
correlation between cellular iron content and R2′ (p < 0.001). n = 18 
2.4 Discussion 
Monocytes are the most abundant cell type during an inflammatory response [2]. As 
such, different monocyte subpopulations reflecting pro- and anti-inflammatory stages 
may potentially serve as biomarkers for monitoring inflammation. In our study, we used 
the human THP-1 monocytic cell line to monitor hepcidin-FPN interactions, which occur 
in only a few cell types and may provide a relatively unique biomarker for molecular 
imaging.  
Iron export in monocytes 
Hepcidin is a polypeptide hormone secreted in response to changes in systemic iron and 
pro-inflammatory cytokines like IL-6. Hepcidin activity downregulates the iron export 
protein, FPN. By culturing monocytes in the presence and absence of hepcidin (200 
ng/ml), while treating the cells with extracellular iron supplementation (25 µM ferric 
nitrate), we investigated the influence of iron export on MR relaxation rates. In addition, 
we measured the cellular iron content and correlated it with MR relaxation rates to better 
understand the relationship between these measures. 
As the main mammalian iron export protein, FPN recycles intracellular iron back to the 
plasma. FPN is only expressed by certain cells, predominantly hepatocytes, enterocytes, 
macrophages and their precursors - the monocytes [15]. In response to inflammation, 
monocytes phagocytose damaged red blood cells and then release the iron recovered from 
heme back into plasma, predominantly for the synthesis of new red blood cells [16]. As 
the expression of FPN is integral to this process, in our study, we confirmed that THP-1 
monocytes express the iron export protein FPN (-Fe, Figure 7A). Relative to the 
housekeeping protein, GAPDH, the expression of FPN is abundant (ratio ~1, Figure 7C). 
These data are supported by literature related to FPN expression in freshly isolated 
human blood monocytes and THP-1 monocytes [17, 18]. Our observations of FPN 
expression in the presence of extracellular iron supplementation (+Fe, Figure 7A) are 
consistent with a study showing an increase in FPN mRNA levels in THP-1 cells under  
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iron supplemented conditions [19]. Given the relatively equal levels of FPN protein +/-Fe 
(by densitometry, Figure 7C), these findings further suggest that FPN turnover, through 
transcriptional and post-translational mechanisms, may both be active in monocytes, in 
the presence of an extracellular iron supplement. FPN protein expression was 
downregulated within 1 to 2 hours after the removal of iron supplement (Figure 7C), 
consistent with post-translational regulation of FPN and consistent with the reported 
production of hepcidin by THP-1 monocytes, which leads to FPN ubiquitination [16, 17]. 
This hypothesis implicates hepcidin autocrine/paracrine activity, which we documented 
upon withdrawal of iron supplementation (in the absence of exogenous hepcidin). We 
note that no further degradation of FPN by exogenously added hepcidin was obtained at 
1h-Fe and 2h-Fe, as would be expected for autocrine/paracrine regulation. 
Interestingly, FPN returns to baseline levels (high expression) by 4h-Fe only to drop 
again at 24h-Fe, indicating a biphasic response to (the presumed) monocyte self-
regulation by hepcidin. The short-lived nature of the active form of hepcidin (hepcidin-
25) permits fine-tuned control of FPN and therefore the iron export function of 
monocytes. 
Hepcidin regulation of monocytes 
When pro-inflammatory signaling through IL-6 promotes inflammation, the hormone 
hepcidin is produced by the liver [20, 21]. Through downregulation of FPN in monocytes 
and macrophages, hepcidin reduces the extracellular iron availability at the site of 
inflammation. Consequently, hepcidin helps fight infection since iron is a critical co-
factor for many microbes [22, 23]. In our study, we detected downregulation of 
ferroportin expression in THP-1 monocytes in response to exogenous hepcidin treatment 
(Figure 7B) whenever monocyte self-regulation did not predominate: at baseline (-Fe), in 
the presence of continuous iron supplementation (mimicking hemorrhage, +Fe), and at 
4h-Fe. Hence, monocytes appear to be subject to endocrine, paracrine and autocrine 
regulation by hepcidin [17]. 
Over the years, clinicians have been struggling to distinguish between pro-inflammatory 
and anti-inflammatory stages post-AMI to prevent unwanted tissue remodeling leading to 
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heart failure [24, 25]. Since monocytes along with hormones like hepcidin travel to the 
infarcted myocardium through systemic circulation post-AMI, we expected that pro-
inflammatory signaling through hepcidin may cause increased iron retention in 
monocytes and facilitate their detection using MRI. In the absence of exogenous hepcidin 
(low/no endocrine signaling), total cellular iron content is not significantly altered by 
changes in extracellular iron (Figure 8A), pointing to the efficiency of autocrine/paracrine 
hepcidin-mediated regulation of iron homeostasis in an iron-exporting cell type. While 
this form of monocyte iron regulation does not influence R1, it is transiently detected by 
R2* (Figure 9A) and specifically the reversible R2′ component (Figure 9C). Indeed, under 
these conditions, there was no correlation between iron and R2; however, there was a 
moderate correlation between iron and both R2* and R2′ (Figure 13). To the extent that R2 
represents protein-bound iron, it appears that autocrine/paracrine regulation of FPN 
largely influences the unbound iron fraction that modulates the R2′ signal. 
Our examination of pseudo-endocrine regulation of FPN, by exogenously added 
hepcidin, resulted in discrete changes not only in total cellular iron content but also in all 
three transverse relaxation rates (Figure 10). Exogenous hepcidin significantly influenced 
R2 (Figure 10B), which reflected the same pattern of changes documented for R2* (Figure 
10A). These MR signals were influenced by both long-term (continuous iron 
supplementation) and short-term (within 24 hours of iron supplement withdrawal) 
changes in extracellular iron. By comparison, R2′ mainly displayed changes over shorter 
time scales, within 24 hours of removing iron supplement (Figure 10C). Moreover, in the 
presence of exogenous hepcidin, the correlations between total cellular iron content and 
transverse relaxation rates were all notable. R2* displayed a significantly strong 
correlation to iron while both R2 and R2′ showed moderate correlations. We note that 
both longitudinal and transverse relaxation rates identify a significant effect of hepcidin 
in the one-hour time frame (1h-Fe), possibly reflecting the short half-life of hepcidin and 
the transient nature of its activity. The changes in iron biochemistry that underlie these 
differential MR responses to autocrine/paracrine and endocrine hepcidin regulation of 
monocytes are considered below. 
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Monocyte iron biochemistry 
Mammalian cells predominantly take up ferric iron (Fe+3) through transferrin-TfRc 
interactions and store it as a biomineral in ferritin, in the ferrous state (Fe+2). In humans, 
there is a positive correlation between serum ferritin and hepcidin indicating they work 
together to promote cellular iron storage [26]. The latter study also reported an increase 
in serum hepcidin expression during inflammation. It is not clear whether the stimulus, 
concentration and/or duration of the hepcidin signal influences the extent of monocyte 
responses to hepcidin activity. Our MR data suggest that iron-stimulated changes in FPN 
expression, resulting in autocrine/paracrine hepcidin activity, are distinct from endocrine 
hepcidin activity.  
In our cell model, in the presence of extracellular iron supplementation (+Fe), there was 
no significant change in the cellular iron content compared to the untreated control 
(Figure 8A). Although another report suggested this may be due to an increase in FPN 
expression in iron-supplemented cells [27], we did not detect any change in iron export 
protein. While we have not ruled out the possibility that low TfRc expression limits iron 
uptake, following both hepcidin and extracellular iron treatment (+Fe, Figure 8B) we 
observed a significant increase in cellular iron content compared to unsupplemented 
controls (-Fe). This finding is consistent with a key role for iron export in the 
maintenance of monocyte iron homeostasis [28].  
Another hypothesis is that hepcidin balances the fraction of iron stored in ferritin versus 
LIP, attenuating the net change in total cellular iron content. Since the form of iron 
cannot be determined through ICP-MS measurements, we have no indication of relative 
levels of iron in ferritin or LIP. This may be important to differentiate in the future as 
studies have shown increased ferritin mRNA expression due to hepcidin [19] as well as a 
positive correlation between monocyte LIP and hepcidin expression [29].  
Where changes in MRI signal in the presence and absence of hepcidin are not 
corroborated by the quantification of iron, we speculate that differences in intracellular 
iron redox status may contribute to changes in transverse relaxivity. Dietrich et al. (2017) 
show a significant increase in R2* of ferric (Fe
+3) compared to ferrous (Fe+2) ions [30]. In 
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addition, House et al. (2007) emphasize that an increase in iron stored as ferritin may 
lead to an increase in R2, partially consistent with our results [31]. The difference in 
correlation times (defined as the time required to rotate by approximately 1 radian) of 
dipolar interactions between the redox state(s) of iron and water protons contributes to 
changes in relaxation rates [30, 32, 33].   
2.5 Conclusions 
Differences in cellular iron handling mechanisms may allow some cell types to be 
tracked using MRI [34]. For example, monocytes are one of the most abundant immune 
cell types in chronic inflammatory conditions like atherosclerosis. In this context, 
hepcidin-mediated changes in iron retention may allow us to track the activity of these 
cells. Toward this goal, we examined human THP-1 monocytes and the effect of hepcidin 
on FPN protein expression, cellular iron content, and MR relaxation rates.  
Since there was little or no change in FPN expression upon iron supplementation (+Fe), 
cellular iron content and MR relaxation rates remained unchanged compared to non-
supplemented monocytes (-Fe). Following the withdrawal of iron supplement, cellular 
iron content remained constant; although, R2* and R2′ significantly increased. In general, 
the addition of hepcidin lead to downregulation of FPN and a significant increase in 
cellular iron content. This finding was reflected in a significant increase in both   
longitudinal and transverse relaxation rates. Moreover, while iron content and R2* were 
positively correlated in the absence of hepcidin, this moderate correlation was 
strengthened by the addition of hepcidin. These results demonstrate the effect of hepcidin 
on THP-1 monocyte iron regulation and the degree to which cellular iron content and 
regulation of iron export activity affect MRI measures. Overall, results from our in vitro 
study suggest that hepcidin-mediated changes in monocyte iron handling could 
potentially be tracked using MRI and may be exploited for monitoring inflammatory 
processes in vivo.     
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Chapter 3 
3.1 Summary 
 In this study, iron regulation in THP-1 monocytes and its influence on MR relaxation 
rates were studied in the presence and absence of hepcidin. We found that (1) human 
THP-1 monocytes express FPN iron export protein in the presence and absence of 
extracellular iron and (2) FPN expression was downregulated in the presence of hepcidin. 
We showed that FPN downregulation is associated with an increase in cellular iron 
content, which likely promotes the observed increase in R2* following hepcidin treatment 
of iron-supplemented cells. Furthermore, we showed that hepcidin-treated cells display a 
strong correlation between total cellular iron content and R2*; whereas, in the absence of 
hepcidin, this was a moderate correlation. Overall, the results from this in vitro study may 
provide possibilities for in vivo tracking of hepcidin-mediated changes (i.e. due to 
inflammation) in monocyte iron-handling (i.e. due to hemorrhage) using MRI.  
3.2 Future work 
In this study, we examined the hepcidin-FPN interactions that govern mammalian iron 
regulation in THP-1 monocytes. In the presence of hepcidin, total cellular iron content is 
altered by changes in extracellular iron. Though these changes may reflect the 
downregulation of FPN by hepcidin, these findings should be further characterized in the 
future by investigating the expression levels of the iron import protein TfRc.   
Although the total cellular iron content of monocytes increased in response to iron 
supplementation in the presence of hepcidin (Figure 4B), no changes in cellular iron 
content were observed between hepcidin treated cells and their untreated counterparts. 
However, differentiating these monocytes into macrophages and distinguishing between 
M1 (iron storage) and M2 (iron recycling) phenotypes may expose further differences in 
iron regulation [1]. Since these two phenotypes have distinct iron handling mechanisms, 
it would be interesting to investigate how changes in extracellular iron supplementation 
influence both the cellular iron content and MR relaxation rates [2, 3]. Since there may be 
a contribution from monocytes and macrophage phenotypes to the MR relaxation rates, it 
would be interesting to co-culture the monocytes and macrophages together and measure 
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the MR relaxation which would provide useful information to track inflammation in vivo.  
Also, it may be important to decipher whether any of these cells have the ability to 
produce hepcidin for autocrine and paracrine signalling [4], and that could be examined 
using basic lab techniques like the enzyme-linked immunosorbent assay (ELISA).  
Changes in the iron redox state, from Fe+2 to Fe+3, and how this influences MR relaxation 
rates are reported in the literature [5-7]. These changes in redox state may contribute to 
the significant increase in MR relaxation once the iron supplementation is withdrawn, 
regardless of hepcidin treatment, and may provide additional insight into monocyte iron 
regulation. In addition, a portion of total cellular iron in these monocytes exists as 
ferritin, representing iron bound to protein, or as iron within the transient LIP, 
representing unbound iron. Current literature indicates that ferritin-bound iron gives rise 
to R2 relaxivity, while iron in the LIP gives rise to R2* relaxivity [8, 9]. Therefore, 
quantifying the relative proportions of ferritin and LIP may provide insight into how iron 
form influences MR relaxation rates. Since iron metabolism is constantly readjusting to 
maintain homeostasis, we expect that the most sustained or long-lived changes would 
arise in the context of chronic inflammation or hemorrhage. 
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Appendix A: Raw data of relaxation rates for THP-1 monocytes in response to 
changes in extracellular iron supplementation. 
R1 Relaxation rate Mean SD SEM 
-Fe 0.83 0.79 0.89  0.84 0.05 0.03 
+Fe 0.85 0.84 0.84  0.84 0.01 0.003 
1h-Fe 0.96 1.09 0.85  0.96 0.12 0.06 
2h-Fe 1.05 1.09 0.84  0.99 0.13 0.07 
4h-Fe 0.95 0.99 0.92  0.95 0.03 0.02 
24h-Fe 0.72 0.84 0.80  0.78 0.06 0.03 
 
R2* Relaxation rate Mean SD SEM 
-Fe 16.86 12.51 14.49 13.00 14.22 1.95 0.98 
+Fe 10.01 15.75 16.56 15.84 14.54 3.04 1.52 
1h-Fe 20.98 21.06 28.13 22.65 23.21 3.37 1.69 
2h-Fe 23.66 27.62 28.98 21.94 25.55 3.30 1.65 
4h-Fe 24.38 26.00 22.17  24.18 1.92 1.11 
24h-Fe 14.06 14.21 14.77  14.35 0.37 0.22 
 
R2 Relaxation rate Mean SD SEM 
-Fe 12.5 10.66 10.14 11.37 11.17 1.02 0.51 
+Fe 5.45 11.98 11.80 11.85 10.27 3.21 1.61 
1h-Fe 13.70 12.72 16.39 13.47 14.07 1.60 0.80 
2h-Fe 13.34 13.95 16.15 13.4 14.21 1.32 0.66 
4h-Fe 17.04 17.44 13.59  16.02 2.12 1.22 
24h-Fe 8.37 10.44 9.86  9.56 1.07 0.62 
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R2ˈ Relaxation rate Mean SD SEM 
-Fe 4.36 1.85 4.35 1.63 3.05 1.51 0.76 
+Fe 4.56 3.77 4.76 3.99 4.27 0.47 0.23 
1h-Fe 7.28 8.34 11.74 9.18 9.14 1.90 0.95 
2h-Fe 10.32 13.67 12.83 8.54 11.34 2.35 1.17 
4h-Fe 7.34 8.56 8.58  8.16 0.71 0.41 
24h-Fe 5.69 3.77 4.91  4.79 0.97 0.56 
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Appendix B: Raw data of relaxation rates for THP-1 monocytes in response to 
changes in extracellular iron supplementation and hepcidin 
R1 Relaxation rate Mean SD SEM 
-Fe 0.72 0.72 0.75  0.73 0.02 0.01 
+Fe 0.94 0.84 0.86  0.88 0.05 0.03 
1h-Fe 0.79 0.82 0.83  0.81 0.02 0.01 
2h-Fe 0.89 0.90 0.90  0.89 0.01 0.003 
4h-Fe 0.96 0.97 0.96  0.96 0.01 0.003 
24h-Fe 0.80 0.81 0.82  0.81 0.01 0.01 
 
R2* Relaxation rate Mean SD SEM 
-Fe 12.94 12.45 14.21  13.20 0.91 0.52 
+Fe 20.75 19.29 21.13  20.39 0.97 0.56 
1h-Fe 15.70 16.27 16.88 17.75 16.65 0.88 0.44 
2h-Fe 29.05 23.88 29.36  27.43 3.10 1.78 
4h-Fe 26.05 21.52 26.08  24.55 2.62 1.52 
24h-Fe 14.72 11.89 17.67  14.76 2.89 1.67 
 
R2 Relaxation rate Mean SD SEM 
-Fe 7.73 8.30 8.63  8.22 0.46 0.26 
+Fe 13.30 12.37 11.37  12.35 0.97 0.56 
1h-Fe 9.83 11.06 11.02 11.93 10.96 0.86 0.43 
2h-Fe 15.32 13.78 17.56  15.55 1.90 1.10 
4h-Fe 16.00 14.48 20.16  16.88 2.94 1.70 
24h-Fe 9.76 9.90 10.59  10.08 0.44 0.26 
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R2ˈ Relaxation rate Mean SD SEM 
-Fe 5.21 4.15 5.58  4.98 0.74 0.43 
+Fe 7.45 6.92 10.11  8.16 1.71 0.99 
1h-Fe 5.87 5.21 5.86 5.82 5.69 0.32 0.16 
2h-Fe 13.73 10.10 12.30  12.04 1.83 1.06 
4h-Fe 10.50 10.94 5.92  9.12 2.78 1.61 
24h-Fe 4.96 1.94 6.54  4.48 2.34 1.35 
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Appendix C: Raw data of densitometry indicating the ratio between FPN and 
GAPDH: without hepcidin 
 
 
 
 
 
 
 
 
 
 
 
 
Densitometry (FPN/GAPDH)  
Experiment 1  2  3 Mean SD SEM 
-Fe 1.050 0.994 0.951 0.998 0.05 0.03 
+Fe 1.120 1.060 0.930 1.037 0.10 0.06 
1h-Fe 0.458 0.016 0.500 0.324 0.20 0.15 
2h-Fe 0.387 0.500 0.383 0.423 0.07 0.04 
4h-Fe 1.150 0.900 0.757 0.936 0.20 0.12 
24h-Fe 0.290 0.029 0.050 0.123 0.15 0.08 
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Appendix D: Raw data of densitometry indicating the ratio between FPN and 
GAPDH: with hepcidin 
 
 
 
 
 
 
 
 
 
 
 
 
Densitometry (FPN/GAPDH)  
Experiment  1  2  3 Mean SD SEM 
-Fe 0.409 0.453 0.423 0.428 0.02 0.01 
+Fe 0.564 0.583 0.507 0.551 0.04 0.02 
1h-Fe 0.493 0.363 0.715 0.552 0.18 0.10 
2h-Fe 0.246 0.256 0.352 0.285 0.06 0.03 
4h-Fe 0.211 0.163 0.292 0.222 0.07 0.04 
24h-Fe 0.141 0.145 0.168 0.151 0.02 0.01 
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Appendix E: Western blots 
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Figure 1. Regulation of ferroportin (FPN) expression in THP-1 monocytes by 
extracellular iron and hepcidin. THP-1 cells were cultured for 7 days in the absence (-
Fe) or presence (+Fe) of iron-supplemented medium containing 25µM ferric nitrate. Cells 
were either harvested immediately or after the withdrawal of iron supplement and culture 
for an additional 1 (1h-Fe), 2 (2h-Fe), 4 (4h-Fe) and 24 (24h-Fe) hours. To examine FPN 
regulation, -Fe and +Fe samples were grown in the presence of 200 ng/ml hepcidin for 
the last 24 hours of culture while hepcidin was added to all other samples after the 
removal of iron supplement. Representative Western blots show the change in FPN 
expression in the absence (A and B) and presence (C and D) of hepcidin. Molecular 
weight standards are indicated on the left while GAPDH provided a loading control. 
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Appendix F: Exponential curves 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Exponential curves of transverse and longitudinal relaxation rates. A. 
Signal decay curve is shown for T2* weighted images for -Fe control condition. Each 
point on the graph represents mean signal intensity measured within a defined ROI and 
plotted against echo times. Exponential fitting was conducted to calculate the transverse 
relaxation rate (R2*). B. The R2* map, representing the phantom was obtained using 
voxel by voxel exponential curve fitting C. Signal growth curve is shown for T1 weighted 
images for the -Fe control condition. Each point on the graph represents mean signal 
intensity measured within a defined ROI and plotted against echo times. Exponential 
fitting was conducted to calculate the longitudinal relaxation rate (R1). D. The R1 map 
representing the phantom was obtained using voxel by voxel exponential curve fitting. 
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